STUDY OF A FIXED COMBINATION OF LISINOPRIL, LONG-ACTING INDAPAMIDE AND AMLODIPINE USING DAILY BLOOD PRESSURE AND DIURESIS MONITORING IN PATIENTS WITH ARTERIAL HYPERTENSION

Aim. To evaluate the efficacy, tolerability and safety of the drug Ekvapress (Gedeon Richter, Hungary) - a new fixed drug combination of ACE inhibitor lisinopril, diuretic indapamide with prolonged action and calcium channel blocker amlodipine in the treatment of patients with hypertension. Materials and methods. In 31 patients with high and very high cardiovascular risk of uncontrolled hypertension II-III degree without severe comorbid pathology using daily self-monitoring of blood pressure and diuresis (SCADDIUR) evaluated the results of a three-month application of a fixed combination of lisinopril (10/20 mg) with indapamide prolonged action (1.5 mg) and amlodipine (5/10 mg). Target BP reduction was achieved in all patients: in dose combination lisinopril 10 mg, indapamide 1.5 mg, amlodipine 5 mg, - in 87.1 percent of pts, with increased dose of lisinopril up to 20 mg - in 9.7% pots and in increased dose of amlodipine up to 10 mg - in 3.2% pts. The antihypertensive effect was characterized by daily circadian stability, accompanied by restoration of the initially disturbed day and night diuretic balance. The treatment was simple with respect to the selection of dosages of the components of the combination, well tolerated by patients, reduced the frequency of meteopathic reactions and did not cause the development of pronounced side effects. The positive properties of the drug combination are largely associated with the use of a prolonged form of indapamide diuretic. Conclusion. Equapress, fp a fixed combination of the ACE inhibitors lisinopril (10/20 mg), prolonged action diuretic indapamide (1.5 mg) and the CCB amlodipine (5/10 mg) has a high antihypertensive efficacy with circadian stability of action, good tolerability and safety of treatment, and also ease selection of the measuring components. Equapress can be used without prior separate titration of doses of components and is recommended for the treatment of patients with hypertension with high and very high cardiovascular risk. In most patients, the starting dose combination (lisinopril 10 mg/indapamide 1.5 mg/amlodipine 5 mg) is effective.

arterial hypertension, self-monitoring of blood pressure, diuresis, combination therapy, angiotensin-converting enzyme inhibitor lisinopril, calcium channel blocker amlodipine, diuretic indapamide, treatment effectiveness